News

Congratulations to the China Children's Cancer Group Acute Lymphoblastic Leukemia (CCCG-ALL) Study Group on its significant global contributions in paediatric oncology.

VIVA Foundation for Children with Cancer (VIVA-Singapore) in Singapore’s partnership and collaboration with VIVA China Children’s Cancer Foundation (VIVA-China) has resulted in tremendous success in the CCCG-ALL Study Group. The CCCG-ALL Study Group has now enrolled over 16,000 children across 26 hospitals in China and Hong Kong SAR and published 23 articles on the findings from the study group’s research. In addition, Dr Cai, Director of VIVA China, established a Survivorship Programme at National Children’s Medical Center and Shanghai Children’s Medical Center, which has produced three high-quality publications, including one expert consensus. The collaborative study culminated in a notably high five-year survival rate of 91% for ALL.  

VIVA-Singapore is excited that our partnership with VIVA-China has profound impact in advancing paediatric ALL research and survivorship care in China and beyond -- for the children with cancer.

We also thank Dr Pui Ching-Hon, our Chair of External Advisory Board (VIVA-Singapore), for his continuous and invaluable support in this collaboration to advance paediatric ALL research and survivorship care in China, Singapore and the region.

CCCG-ALL Study Group Publications